Baculovirus Produced P. falciparum Vaccine

Category: Biology and Medicine

Reference Number: 00096

Description

The technology covers the construct consisting of the baculovirus polyhedron promoter, the yeast flg5 leader sequence, and the p42 MSP1 sequence with the transmembrane domain deleted cloned at the University of Hawaii from the Uganda-Palo Alto isolate of P. falciparum. The patent application also considers the production of other, related p42 constructs based on allelic and variant sequences expressed by other isolates of P. falciparum.

Applications

Malaria vaccine.

Main Advantages

The p42 MSP1 recombinant polypeptide produced by recombinant baculoviruses expressing this construct in insect cell culture possesses several properties which make it particularly attractive as a malaria vaccine: (1) reactivity with a panel of monoclonal antibodies produced against native, parasite MSP1 indicate that it possesses disulfide-dependent, conformational determinants which are characteristic of the native protein, (2) immunogenicity studies have indicated that it is highly immunogenic, inducing very high antibody titers in rabbits and non-human primates (Aotus) and priming both type 1 and type 2 cytokine responses (Aotus), (3) a vaccination study has demonstrated that BVp42, when combined with an adjuvant such as Complete Freund’s Adjuvant, induces a protective immune response against P. falciparum infection in non-human primates (Aotus).

Inventor(s)

Sandra Chang
George Hui
Tropical Medicine & Medical Microbiology

Philip Barr
Helen Gibson
Chiron Corporation

Contact Information

For licensing information, please contact Lisa Matsunaga at matsunag@hawaii.edu

For all other inquiries, please write to:

Office of Technology Transfer & Economic Development
University of Hawai’i
2800 Woodlawn Drive, Suite 280
Honolulu, HI 96822